BMY-27709

TargetMol
Product Code: TAR-T26873
Supplier: TargetMol
CodeSizePrice
TAR-T26873-1mg1mg£352.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T26873-5mg5mg£736.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T26873-10mg10mg£978.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T26873-25mg25mg£1,348.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T26873-50mg50mg£1,661.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T26873-100mg100mg£2,079.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T26873-500mg500mg£4,006.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
BMY-27709 is an inhibitor of influenza virus growth with an IC50 of 3-8 microM for A/WSN/33 virus growth and is also active against all H1 and H2 subtype viruses tested. BMY-27709 acted against H1 and H2 viruses early in infection, suggesting that the target for inhibition is the hemagglutinin protein. However, BMY-27709 was found to be inactive against H3 subtype viruses, as well as influenza B/Lee/40 virus.
CAS:
99390-76-8
Formula:
C17H24ClN3O2
Molecular Weight:
337.85
Pathway:
Microbiology/Virology
Purity:
0.98
SMILES:
C[C@@H]1CCC[C@@H]2C[C@H](CCN12)NC(=O)c1cc(Cl)c(N)cc1O
Target:
Influenza Virus

References

1. Hsieh HP, Hsu JT. Strategies of development of antiviral agents directed against influenza virus replication. Curr Pharm Des. 2007;13(34):3531-42. Review. PubMed PMID: 18220789. 2. Yu KL, Torri AF, Luo G, Cianci C, Grant-Young K, Danetz S, Tiley L, Krystal M, Meanwell NA. Structure-activity relationships for a series of thiobenzamide influenza fusion inhibitors derived from 1,3,3-trimethyl-5-hydroxy-cyclohexylmethylamine. Bioorg Med Chem Lett. 2002 Dec 2;12(23):3379-82. PubMed PMID: 12419365. 3. Deshpande MS, Wei J, Luo G, Cianci C, Danetz S, Torri A, Tiley L, Krystal M, Yu KL, Huang S, Gao Q, Meanwell NA. An approach to the identification of potent inhibitors of influenza virus fusion using parallel synthesis methodology. Bioorg Med Chem Lett. 2001 Sep 3;11(17):2393-6. PubMed PMID: 11527739. 4. Combrink KD, Gulgeze HB, Yu KL, Pearce BC, Trehan AK, Wei J, Deshpande M, Krystal M, Torri A, Luo G, Cianci C, Danetz S, Tiley L, Meanwell NA. Salicylamide inhibitors of influenza virus fusion. Bioorg Med Chem Lett. 2000 Aug 7;10(15):1649-52. PubMed PMID: 10937716.